We did not see consistent re-expression of genes that have been previously reported to be under epigenetic control and/or reactivated by low concentration of decitabine (0.1 μM) in established uveal melanoma cell lines, such as S100A2 [24], and two melanoma cell lines, such as Apo2L/TRAIL and XAF1 [18], or in response to higher concentrations of decitabine, such as PTEN, HOXB13, APC, RASSF1A, RARB and MGMT[10], [25], [26]. The gene discussed is S100A2; the disease is melanoma.